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Abstract
Purpose—To determine which medications are most commonly used by women in the first 
trimester of pregnancy and identify the critical gaps in information about fetal risk for those 
medications.
Methods—Self-reported first-trimester medication use was assessed among women delivering 
liveborn infants without birth defects and serving as control-mothers in two large case-control 
studies of major birth defects. The Teratology Information System (TERIS) expert Advisory 
Board ratings of quality and quantity of data available to assess fetal risk were reviewed to 
identify information gaps.
Results—Responses from 5,381 mothers identified 54 different medication components used in 
the first trimester by at least 0.5% of pregnant women, including 31 prescription and 23 over-the-
counter medications. The most commonly used prescription medication components reported were 
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progestins from oral contraceptives, amoxicillin, progesterone, albuterol, promethazine, and 
estrogenic compounds. The most commonly used over-the-counter medication components 
reported were acetaminophen, ibuprofen, docusate, pseudoephedrine, aspirin, and naproxen. 
Among the 54 most commonly used medications, only two had ‘Good to Excellent’ data available 
to assess teratogenic risk in humans, based on the TERIS review.
Conclusions—For most medications commonly used in pregnancy, there are insufficient data 
available to characterize the fetal risk fully, limiting the opportunity for informed clinical 
decisions about the best management of acute and chronic disorders during pregnancy. Future 
research efforts should be directed at these critical knowledge gaps.
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Introduction
In the last three decades, use of medications during pregnancy has increased. In 2006-2008, 
over 90% of women reported using at least one prescription or over-the-counter medication 
during pregnancy, and over 80% reported use during the first trimester, a critical period of 
organogenesis.1 Because pregnant women are typically excluded from clinical trials for new 
medications and animal findings may not predict human effects, the teratogenicity of new 
medications in humans is usually not well characterized at the time of initial marketing. 
Based on an analysis performed in 2011 using Teratology Information System (TERIS) 
expert reviews, among 172 medications approved for use in the United States between 
2000-2010, 70% had no human data and 98% had insufficient published data to determine 
teratogenic risk in humans.2 Prior analyses provided prevalence estimates for specific 
prescription1 and over-the-counter medications;3 we sought to update and extend this work 
by creating an updated list of the most commonly used medications in pregnancy and 
assessing the quantity and quality of information regarding teratogenic risks that is available 
to inform clinical decisions for these medications.
Methods
The pregnancy exposures for mothers of control-infants (liveborn infants with no major 
birth defects) from two large multi-site case-control studies, the Slone Epidemiology 
Center’s Birth Defects Study (BDS) and the CDC-coordinated National Birth Defects 
Prevention Study (NBDPS), were used to estimate the prevalence of first trimester 
medication component use. Detailed methods for BDS and NBDPS have been described 
previously.1 Briefly, both studies gather self-reported prescription and over-the-counter 
medication exposures via computer assisted telephone interviews that are designed to 
prompt recall for medication use and timing of use.4 To update previously-described 
prescription and over-the-counter medication prevalence estimates,1,3 we limited analyses to 
the most current 4-year time period of data available for control mothers in each study: 
births between January 1, 2006, and December 31, 2009, in BDS or those with an estimated 
due date between January 1, 2004, and December 31, 2007, in NBDPS. Because the studies 
have different timelines for conducting maternal interviews (BDS data are available sooner 
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than NBDPS data), the time periods available were not identical. The Slone Drug Dictionary 
(Boston University) was used to identify the individual components for each reported 
medication (e.g., use of acetaminophen with codeine counted as one exposure to 
acetaminophen and one exposure to codeine). We excluded medications used exclusively 
intravenously, locally (e.g., procaine), or topically, but included those used intra-vaginally. 
Medications reported by type but not by specific name (e.g., antibiotic, not otherwise 
specified) were excluded. Due to variability in preparations, vitamins, minerals, herbal 
supplements and vaccines were also excluded.
Prevalence of first trimester use of medication components was estimated for each study 
(BDS and NBDPS). We compared the prevalence estimates between the two studies and 
calculated a pooled estimate. Medication components reported by at least 0.5% of control-
mothers in the first trimester of pregnancy based on the pooled data were defined as those 
most commonly used and were included in this analysis.
To obtain a rating of the quality and quantity of information available regarding human 
teratogenic risk for these frequently-used medication components, we searched the TERIS 
database.5 TERIS rates the risk of permanent abnormality of structure or function in a child 
as a result of maternal exposure during pregnancy to commonly encountered doses of an 
agent. The rating is based on consensus of the TERIS authors and six internationally-
recognized authorities in clinical teratology who comprise the TERIS Advisory Board. The 
assessment is made on the basis of the reproducibility, consistency, and biological 
plausibility of published clinical, epidemiological, and experimental data for each exposure. 
The TERIS summary also rates the available data on which the risk evaluation is based as 
None, Limited, Fair, Good, Excellent, or in an intermediate category, such as Fair to Good. 
Risk assessments based on evidence that is Limited or Fair are considered to be tentative 
and may change as more information becomes available. Even with Good data, only crude 
estimates of the magnitude of the risk are often possible. While the broader goal is to inform 
the fetal risk of medication exposure, we did not include the magnitude of risk from TERIS 
because the focus of this analysis is the existing gaps in available evidence for decision-
making. We included the Food and Drug Administration (FDA) pregnancy category label 
(A, B, C, D, or X) of each prescription component.6 These categories are assigned at the 
time of marketing approval and take into account both the available data on risks of various 
adverse reproductive outcomes (usually from animal studies) and the benefit of maternal 
treatment during pregnancy. However, they are not systematically updated on the basis of 
subsequent studies.7 Because the FDA does not require pregnancy categories be published 
on product labels for over-the-counter medications, such information is not routinely 
available for clinical and individual decision making, and therefore was not included in this 
analysis.
Results
Responses from 5,381 mothers of infants without major birth defects were included: 1,923 
from BDS and 3,458 from NBDPS. The prevalence estimates for each medication 
component varied little between the studies despite minor methodological differences and 
independent study populations (Table 1 and Table 2). Based on pooled prevalence estimates, 
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we found that 54 unique medication components were used by 0.5% or more of women in 
the first trimester of pregnancy: 23 over-the-counter and 31 prescription medication 
components. The most common types of medications included analgesics, laxatives, cough 
and cold remedies, oral contraceptives, antibiotics, antihistamines, asthma medications, and 
antacids. The most common specific prescription components included progestins from oral 
contraceptives, amoxicillin, progesterone, albuterol, promethazine and estrogenic 
compounds; over-the-counter components included acetaminophen, ibuprofen, docusate, 
pseudoephedrine, aspirin, and naproxen.
Based on the TERIS rating of the quantity and quality of data available to assess the 
teratogenic risk, 34 (63%) of these medication components had Very Limited to Fair data, 
18 (33%) had Fair to Good data, and 2 (4%) (promethazine and doxylamine) had Good to 
Excellent data available (Tables 1 and 2). The 31 prescription medications used most 
commonly included 1 (3%) in FDA Pregnancy Category A, 9 (29%) in Category B, 12 
(39%) in Category C, 2 (6%) in Category D, and 7 (23%) in Category X (Table 2).
Discussion
The reported prevalence, based on responses from control mothers from two large multi-site 
studies, represents the most robust contemporary estimate available for use of medications in 
the first trimester of pregnancy in the United States and provides a more current 
comprehensive listing of both prescription and over the counter medications. The prevalence 
estimates are quite similar in the two studies. When compared to estimates from previous 
analyses from these studies,1,3 the ranking of medications has shifted slightly, likely 
reflecting changes in use that occur over time. This analysis also extends earlier work to 
address the critical gaps in our understanding of fetal risks. Based on the quality and 
quantity of available data assessed by TERIS, only 2 (4%) of the 54 most commonly used 
medications received a Good to Excellent rating of quality and quantity data available to 
assess teratogenic risk. Some exposures were likely inadvertent, such as use of progestins 
(presumably from failed contraceptive use) in early pregnancy. For the vast majority of the 
commonly used medications, insufficient data exist to characterize fully the fetal risk when 
used during pregnancy, limiting opportunities for informed clinical decisions about the best 
management of maternal conditions.8
Medication use during pregnancy is common and has increased approximately 68% over the 
past 30 years in the United States.1 Factors potentially contributing to this trend include 
chronic health conditions associated with increased maternal age and the growing use of 
medication in the U.S. population.9,10 Numerous health conditions such as infections, 
asthma, and depression may require treatment during pregnancy, but there is little guidance 
available to inform clinical practice. A recent American College of Obstetricians and 
Gynecologists (ACOG) committee opinion provided some guidance on use of antibiotics 
during pregnancy, but even for the medications cited improved data are needed to permit a 
more robust evaluation of the risk versus benefit for specific situations.11
While prescription medications are assigned an FDA pregnancy category as part of the 
FDA-approved label, these categories can be misinterpreted. For example, progestins found 
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in oral contraceptives are labeled as category X, presumably because they provide no 
clinical benefit as contraceptives during pregnancy. However, when these agents are 
inadvertently used in pregnancy, available data indicate that the teratogenic risk is small or 
non-existent.8,12 The FDA is transitioning to a new, expanded labeling system that will 
provide improved information to women and their health care providers by including a 
description of the available data and what is known with regard to human teratogenic risk.13 
Despite this new labeling system, the insufficiency of data available remains a concern.
A potential limitation of our findings is that all medication exposures were self-reported 
after pregnancy by women who delivered liveborn infants without major birth defects. 
Women might underreport less memorable exposures or their reports may lack specificity 
among similar products (e.g., single component versus multi-component acetaminophen 
products), but the BDS and NBDPS studies are designed to maximize recall accuracy by 
specifically probing for medication use by indication and by named medications.4 While 
limitations exist with self-reported data, analyses based solely on medical and pharmacy 
records do not capture over-the-counter medications, nor prescriptions that have been saved 
or borrowed from others.14 Finally, the TERIS evaluation of the quality and quantity of 
available information is made by an expert advisory board, and the specific composition of 
the panel could influence their ratings and our findings.
The current study highlights the lack of available information regarding fetal safety for 
medications commonly used in pregnancy. While steps are being taken to improve clinical 
decision making by revising the FDA labeling to convey more detailed and specific 
information, significant evidence gaps exist in understanding the teratogenic risk of the vast 
majority of medications used in early pregnancy. While adequate evidence to inform every 
decision about every pregnancy might not be possible, addressing these critical gaps has the 
potential to improve both fetal and maternal health, and research efforts should be directed 
towards this goal.
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1. This report updates the list of the most commonly used medications in the first 
trimester of pregnancy in the United States.
2. Teratogenic risk of the most commonly used medications has not been 
adequately studied in human pregnancy.
3. Improved understanding of the fetal risk associated with medication use during 
pregnancy could better inform clinical decisions regarding treatment.
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Table 1
Commonly used over-the-counter medication components* in the first trimester of pregnancy and their 
TERIS** data ratings, the Slone Epidemiology Center’s Birth Defects Study (BDS) (2006-2009) and the 
National Birth Defects Prevention Study (NBDPS) (2004-2007)
Percent reporting use
BDS NBDPS Pooled TERIS Data Rating**
Over-the-counter (N=1923) (N=3458) (N=5381)
medication components
Acetaminophen 55.2 56.1 55.8 Fair to Good
Ibuprofen 26.3 21.9 23.5 Fair to Good
Docusate 4.8 8.7 7.3 Fair
Pseudoephedrine 5.7 6.8 6.4 Fair
Aspirin 8.1 3.7 5.3 Good
Naproxen 5.1 3.9 4.3 Limited to Fair
Diphenhydramine 5.9 2.3 3.6 Fair
Loratadine 4.7 2.8 3.4 Fair
Dextromethorphan 2.1 3.3 2.9 Limited to Fair
Guaifenesin 2.6 2.1 2.3 Fair
Cetirizine 2.3 1.5 1.8 Limited to Fair
Doxylamine 1.2 2.1 1.8 Good to Excellent
Bismuth Subsalicylate 4.0 0.4 1.6 Limited
Chlorpheniramine 0.7 1.8 1.4 Fair to Good
Fexofenadine 1.3 1.4 1.4 Very Limited
Phenylephrine 2.2 0.7 1.3 Fair to Good
Ranitidine 1.6 0.4 0.9 Fair to Good
Miconazole 1.6 0.3 0.7 Fair
Famotidine 1.3 0.3 0.7 Limited to Fair
Simethicone 0.8 0.5 0.6 Very Limited
Psyllium 1.3 0.2 0.6 Limited to Fair
Omeprazole 0.8 0.4 0.5 Fair to Good
Oxymetazoline 0.9 0.2 0.5 Limited to Fair
*
Varying strengths of the same component were combined. Commonly used was defined as exposure to any component in the first trimester as 
reported by 0.5% or more women. Multiple exposures to the same component in the first trimester were counted only once.
**
Teratology Information System (TERIS) - The data available on which the risk assessment is based is rated as None, Limited, Fair, Good, or 
Excellent. Risk assessments based on evidence that is Limited or Fair ought to be considered tentative and may change as more information 
becomes available. Even with Good data, only crude estimates of the magnitude of the risk are often possible. Each agent is based on a consensus 
of ratings by seven internationally-recognized authorities in clinical teratology.













Thorpe et al. Page 9
Table 2
The most commonly used prescription medication components* in the first trimester of pregnancy, their Food 
and Drug Administration (FDA) pregnancy categories and TERIS** data ratings, Slone Epidemiology Center’s 
Birth Defects Study (BDS) (2006-2009) and the National Birth Defects Prevention Study (NBDPS) 
(2004-2007)
Percent reporting use FDA
Prescription BDS NBDPS Pooled Pregnancy TERIS Data
medication components (N=1923) (N=3458) (N=5381) Category Rating**
Progestinsa 5.2 4.4 4.7 X Good
Amoxicillin 2.3 4.6 3.8 B Good
Progesterone 4.2 2.9 3.4 X Good
Albuterol 4.2 2.8 3.3 C Limited
Promethazine 0.8 4.3 3.1 C Good to Excellent
Estrogenic compoundsb 2.9 3.0 2.9 X Good
Levothyroxine 3.8 2.3 2.8 A Fair
Ondansetron 3.7 2.1 2.7 B Limited
Azithromycin 2.2 1.7 1.9 B Limited to Fair
Clomiphene 1.3 2.0 1.8 X Fair to Good
Sertraline 1.2 1.7 1.5 C Fair
Fluticasone 2.0 1.2 1.5 C Limited to Fair
Follitropinc 2.6 0.9 1.4 X Very Limited
Hydrocodone 1.4 1.3 1.3 C Limited
Nitrofurantoin 1.5 1.2 1.3 B Fair to Good
Fluoxetine 0.9 1.0 1.0 C Fair
Leuprolide 1.1 0.9 1.0 X Limited to Fair
Salmeterol 1.1 0.8 0.9 C Limited
Bupropion 0.6 1.0 0.9 C Limited to Fair
Metformin 1.2 0.6 0.8 B Fair
Oxycodone 0.9 0.8 0.8 B Limited
Insulin 1.0 0.7 0.8 B Fair
Codeine 0.8 0.7 0.8 C Fair to Good
Metoclopramide 0.8 0.6 0.7 B Fair to Good
Escitalopram 0.9 0.5 0.7 C Limited
Montelukast 0.7 0.5 0.6 B Limited
Chorionic gonadotropind 0.8 0.4 0.6 X Limited to Fair
Paroxetine 0.3 0.7 0.6 D Good
Trimethoprim 0.3 0.7 0.5 C Good
Sulfamethoxazole 0.3 0.7 0.5 C Limited
Alprazolam 0.6 0.5 0.5 D Fair to Good
*
Varying strengths of the same component were combined. Commonly used was defined as exposure to any component in the first trimester as 
reported by 0.5% or more of women. Multiple exposures to the same component in the first trimester were counted only once.
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**
Teratology Information System (TERIS) - The data available on which the risk assessment is based is rated as None, Limited, Fair, Good, or 
Excellent. Risk assessments based on evidence that is Limited or Fair ought to be considered tentative and may change as more information 
becomes available. Even with Good data, only crude estimates of the magnitude of the risk are often possible. Each agent is based on a consensus 
of ratings by seven internationally-recognized authorities in clinical teratology.
a
Progestins include desogestrel, etonogestrel (pill and implant), levonorgestrel, medroxyprogesterone, noregelgestromin, norethindrone, 
norgestimate, NOS-Oral contraceptive, and NOS-Oral contraceptive (progestin only); but excludes drospirenone (progesterone receptor agonist/
antagonist) and hydroxyprogesterone.
b
Estrogenic compounds include ethinyl estradiol, estradiol cypionate and NOS-estrogen.
c
Follitropin includes follicle-stimulating hormone (FSH), follitropin alpha, and follitropin beta and urofollitropin.
d
Chorionic gonadotropin includes gonadotropin chorionic and choriogonadotropin alfa.
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